Ticker

Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.

Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail prescription data up to 21 August 2026.

The U.S. Food and Drug Administration (FDA) on Tuesday warned patients and healthcare providers about severe health risks linked to unapproved and compounded glucagon-like peptide-1 (GLP-1) weight-loss medications.

Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.